follow us
disclaim warranti liabil
due number sourc inform servic acquisdata pti ltd servic obtain
inher hazard electron distribut may delay omiss inaccuraci inform
servic acquisdata pti ltd affili agent sale repres distributor licensor
warrant accuraci complet current merchant abil fit particular purpos
inform servic avail acquisdata pti ltd servic event acquisdata pti ltd
affili agent sale repres distributor licensor liabl license anyon els loss
injuri caus whole part conting beyond control procur compil interpret edit write
report deliv inform servic acquisdata pti ltd servic event acquisdata
pti ltd affili agent sale repres distributor licensor liabl license anyon els
decis made action taken license relianc upon inform servic consequenti
special similar damag even advis possibl damag license agre liabil
acquisdata pti ltd affili agent sale repres distributor licensor aris kind
legal claim whether contract tort otherwis way connect acquisdata pti ltd servic shall
exceed amount license paid use acquisdata pti ltd servic twelv month immedi
preced event give rise claim
full-year revenu billion reflect oper declin exclud impact consum
oper growth biopharma primarili driven ibranc eliqui xeljanz vyndaqel well
oper growth emerg market
oper declin upjohn primarili due loss exclus lyrica
fourth-quart revenu billion reflect oper declin exclud impact
oper growth biopharma oper declin upjohn
full-year report dilut adjust dilut fourth-quart
report adjust dilut
provid full-year guidanc total new
total revenu guidanc billion adjust dilut
assum full-year contribut biopharma upjohn share repurchas
midpoint new revenu guidanc rang impli oper growth compar
new york ny tuesday januari pfizer inc nyse report financi result fourthquart
full-year provid financi guidanc
acquisit contribut pfizer consum healthcar busi gsk consum healthcar joint
ventur jv complet impact financi result period present amount
press releas may add due round percentag calcul use unround amount
refer oper varianc pertain period-over-period growth rate exclud impact foreign
upon close consum healthcar jv transact third-quart deconsolid
consum healthcar segment result shift record revenu expens contribut
consum healthcar segment record pro rata share earn gener consum
healthcar adjust incom /deduct one-quart lag therefor full-year revenu
reflect seven month consum healthcar segment domest oper eight month consum
healthcar segment intern oper full-year adjust dilut ep likewis reflect seven month
domest segment oper eight month intern segment oper well pro rata share
two month consum healthcar jv earn gener third-quart record
pfizer adjust incom /deduct fourth-quart
financi guidanc total compani adjust adjust dilut
reflect share jv earn gener fourth-quart record
first-quart well share jv project earn first three quarter
shift biopharma upjohn meridian medic meridian pfizer-mylan strateg
collabor japan mylan-japan
begin upjohn began manag pfizer meridian subsidiari manufactur epipen auto-
injector product mylan-japan collabor gener drug japan establish result
revenu expens associ meridian mylan-japan report pfizer upjohn busi
begin first-quart revenu meridian mylan-japan record pfizer
biopharma busi total million flat oper compar full-year
guidanc upjohn
financi guidanc upjohn reflect inclus revenu expens associ meridian
mylan-japan previous record pfizer biopharma busi except shift meridian
mylan-japan biopharma upjohn oper chang upjohn financi
compar preliminari financi target provid juli
midpoint revenu guidanc rang impli oper declin compar full-year upjohn
revenu adjust includ meridian mylan-japan
full-year return billion directli sharehold combin
billion dividend compos quarterli dividend per share common stock
billion share repurchas compos billion open-market share repurchas firstquart
billion acceler share repurchas agreement execut februari complet august
full-year dilut weighted-averag share use calcul earn per common share million
share reduct million share compar full-year
januari remain share repurchas author billion share repurchas
current plan
dr albert bourla chairman chief execut offic state busi year highlight solid
financi perform shareholder-friendli capit alloc strengthen pipelin well
format consum healthcar jv gsk also announc definit agreement combin upjohn
creat new global pharmaceut compani viatri mark import mileston pfizer
evolut toward becom focus global leader innov medicin
expect excit year close upjohn-mylan transact anticip mid-
year leav new posit deliv revenu adjust dilut growth expect
among industri leader new smaller science-bas compani singular focu innov
also continu alloc signific capit directli sharehold primarili dividend
new pfizer expect import clinic data readout across early- mid- late-stag pipelin first
half expect report pivot top-lin result jade compar studi abrocitinib
janu inhibitor moderate-to-sever atop dermat ad three phase trial pf-
pneumococc conjug vaccin candid adult age older xeljanz
ankylos spondyl addit potenti registration-en phase anchor studi evalu
combin braftovi mektovi cetuximab first-lin treatment metastat
colorect cancer also expect data first half promis earlierstag opportun includ
proof-of-concept readout mini-dystrophin gene therapi candid duchenn muscular
dystrophi prophylact vaccin candid prevent respiratori syncyti viru
infect investig topic dual inhibitor psoriasi ad
second half look forward top-lin result phase penelope-b studi ibranc
early-stag breast cancer well proof-of-concept readout dual inhibitor
potenti treatment vitiligo potenti treatment psoriat arthriti pf-
investig inhibitor psoriasi addit expect phase palla studi
ibranc early-stag breast cancer complet earli focus acceler pipelin
build busi momentum gener dr bourla conclud
frank damelio chief offic execut vice presid busi oper global suppli
state pleas financi result met exceed compon financi
guidanc biopharma busi gener oper revenu growth driven strong growth ibranc
eliqui xeljanz vyndaqel/vyndamax expect upjohn busi declin oper primarili
reflect loss exclus lyrica juli exclud lyrica impact recent
product loss exclus upjohn revenu declin oper also return billion
directli sharehold share repurchas dividend demonstr continu commit
return capit sharehold
today also provid financi guidanc total new midpoint
revenu guidanc rang new impli oper growth reflect anticip continu
strong growth certain in-lin brand ibranc eliqui xeljanz xtandi inlyta recent
expect product launch vyndaqel/vyndamax braftovi mektovi oncolog biosimilar well
emerg market sinc juli sever aforement product perform better
anticip gener strong momentum expect continu midpoint revenu
guidanc rang impli oper declin primarili reflect expect declin product
recent lost market exclus lower revenu china due geograph expans
volume-bas procur vbp program chines provinc importantli financi guidanc
remain unchang oper basi preliminari financi target provid
fourth-quart revenu total billion decreas billion compar prior-year
quarter reflect oper declin billion well unfavor impact foreign exchang
million
fourth-quart biopharma revenu total billion oper primarili driven
eliqui global oper primarili driven continu increas adopt non-valvular atrial
fibril well oral anti-coagul market share gain
vyndaqel/vyndamax global revenu million driven
 launch vyndaqel may vyndamax septemb treatment transthyretin
amyloid cardiomyopathi attr-cm
oper growth intern market primarili driven march launch attr-cm
indic japan continu uptak transthyretin amyloid polyneuropathi indic develop
ibranc global oper primarili driven
growth primarili driven cyclin-depend kinas class market share growth
ibranc continu market share leadership approv metastat breast cancer indic
oper growth intern market reflect continu strong uptak follow launch primarili
hospit busi emerg market collect oper primarili driven
continu growth anti-infect product china well novemb launch panzyga
 revenu growth pfizer centreon contract manufactur busi
prevenar emerg market oper primarili reflect overal favor impact time
associ govern purchas pediatr indic compar prior-year quarter well
continu pediatr uptak china
inlyta primarili driven increas uptak result second-quart food
drug administr fda approv combin certain immun checkpoint inhibitor plu inlyta
first-lin treatment patient advanc renal cell carcinoma rcc
xeljanz global oper primarili driven
oper growth intern market reflect continu uptak rheumatoid arthriti ra
indic well recent launch ulcer coliti uc indic certain develop market
growth reflect continu volum growth launch uc indic
off-set higher rebat new commerci contract
xtandi primarili driven continu uptak metastat non-metastat castration-
partial off-set primarili lower revenu
enbrel intern oper primarili reflect continu biosimilar competit
develop europ market
prevnar reflect continu declin revenu adult indic due
declin catch opportun compar prior-year quarter
upjohn revenu highlight fourth-quart upjohn revenu total billion oper
primarili driven expect signific volum declin lyrica due multi-sourc gener
competit began juli exclud unfavor impact lyrica recent product
loss exclus fourth-quart revenu upjohn declin oper
fourth-quart upjohn revenu china declin oper primarili driven declin lipitor
norvasc provinc vbp program implement partial off-set product impact
vbp implement includ celebrex viagra well oper growth lipitor norvasc
provinc vbp implement
fourth-quart full-year si favor
impact juli complet consum healthcar jv transact
record lower fourth-quart compar prior-year quarter primarili
driven
lower asset impair charg billion fourth-quart primarili relat eucrisa
acquir connect pfizer acquisit anacor pharmaceut inc compar asset
impair charg billion fourth-quart primarili associ gener steril inject
product acquir connect pfizer acquisit hospira inc
higher net gain invest equiti secur
lower busi legal entiti align cost
lower net realiz loss sale invest debt secur
partial off-set primarili
higher charg certain legal matter
higher pension post-retir benefit cost
pfizer effect tax rate report fourth-quart compar prior-year quarter
favor impact primarili
benefit relat certain tax initi associ implement new organiz structur
favor chang jurisdict mix earn result oper fluctuat normal cours
partial off-set primarili
decreas tax benefit associ resolut certain tax posit pertain prior year primarili
variou foreign tax author
non-recurr certain tax initi favor adjust record provision estim
legisl commonli refer tax cut job act
addit aforement factor impact effect tax rate report fourthquart
full-year effect tax rate report compar prior year impact
primarili
tax benefit relat settlement intern revenu servic audit multipl tax year
partial off-set primarili
tax expens associ billion pre-tax gain record third-quart relat
complet consum healthcar jv transact
fourth-quart dilut weighted-averag share outstand use calcul dilut ep declin
million share compar prior-year quarter primarili due share repurchas program
reflect impact share repurchas partial off-set dilut relat share-bas
full-year revenu total billion decreas billion compar full-year reflect
oper declin million unfavor impact foreign exchang billion
full-year biopharma revenu total billion oper primarili driven
continu uptak ibranc eliqui xeljanz vyndaqel/vyndamax global
prevenar emerg market
inlyta
partial off-set primarili lower revenu
enbrel intern
prevnar
full-year upjohn revenu total billion oper primarili driven lyrica
due multi-sourc gener competit began juli viagra due increas gener
competit follow decemb patent expir exclud unfavor impact lyrica
recent product loss exclus full-year revenu upjohn declin oper
full-year upjohn revenu china grew oper primarili driven product impact
vbp implement includ viagra celebrex zoloft lyrica well lipitor norvasc provinc
vbp program implement partial off-set revenu declin lipitor norvasc
provinc impact march vbp program implement
full-year revenu consum healthcar total billion oper reflect juli
complet consum healthcar jv transact
decemb committe medicin product human use chmp european medicin
agenc ema adopt posit opinion recommend approv amspar biosimilar
adalimumab treatment certain patient ra juvenil idiopath arthriti axial spondyloarthr
psoriasi hidraden suppurativa crohn diseas uc uveiti pediatr plaqu psoriasi chmp
opinion review european commiss ec final decis expect come
month current plan commerci amspar eu approv ec due
unfavor market condit
novemb announc fda approv abrilada adalimumab-afzb biosimilar
adalimumab treatment certain patient ra juvenil idiopath arthriti
ankylos spondyl adult crohn diseas uc plaqu psoriasi work make abrilada
avail patient soon feasibl base term agreement current plan
launch abrilada
januari emd serono biopharmaceut busi merck kgaa darmstadt germani
canada announc phase javelin bladder studi met primari endpoint
overal surviv os plan interim analysi studi patient previous untreat local advanc
metastat urotheli carcinoma whose diseas progress induct chemotherapi
random receiv first-lin mainten therapi bavencio best support care bsc live
significantli longer receiv bsc statist signific improv os
demonstr bavencio arm coprimari popul random patient patient
tumor safeti profil bavencio trial consist javelin
monotherapi clinic develop program result studi submit present
upcom medic congress share fda health author
novemb emd serono announc top-line result phase javelin gastric studi
evalu avelumab first-lin mainten therapi follow induct chemotherapi patient
unresect local advanc metastat gastric gastroesophag junction cancer versu
continu chemotherapi bsc studi show clinic activ avelumab set
meet primari endpoint superior os compar standard care overal intent-to-treat
popul popul new safeti signal observ safeti profil
avelumab trial consist observ overal javelin clinic develop program
result studi submit present upcom medic congress
braftovi encorafenib -- decemb announc fda accept grant prioriti review
compani supplement new drug applic snda braftovi combin cetuximab
base result phase beacon trial evalu efficaci safeti braftovi
combin erbitux without mektovi binimetinib patient advanc
metastat colorect cancer mcrc follow one two line therapi snda prescript drug user
fee act goal date decis fda april
eliqui apixaban -- decemb bristol-my squibb-pfiz allianc announc result american
societi hematolog annual meet confer retrospect real-world data analys report
outcom safeti effect eliqui compar low molecular weight heparin lmwh warfarin
treatment venou thromboembol vte patient activ cancer result primari analysi
show eliqui use associ lower rate major bleed clinically-relev non-major crnm
bleed recurr vte compar lmwh eliqui also associ lower rate recurr vte
similar rate major bleed crnm bleed compar warfarin second oral present
confer result subgroup analysi primari studi highlight base differ level risk
develop recurr vte studi find gener consist primari analysi
vyndaqel tafamidi -- decemb announc chmp ema adopt posit opinion
recommend approv vyndaqel once-daili mg oral capsul treatment wild-typ hereditari
transthyretin amyloidosi adult patient cardiomyopathi chmp opinion review ec
final decis expect come month
decemb announc fda approv xeljanz xr extended-releas mg mg
tablet once-daili treatment adult patient moder sever activ uc inadequ
respons intoler tnf blocker
novemb announc chmp ema adopt final opinion follow re-evalu
benefit/risk three approv indic xeljanz european union eu re-evalu
initi follow initi announc regard increas occurr pulmonari embol
increas overal mortal xeljanz mg twice daili found on-going postmarket requir studi
ra patient year age older least one cardiovascular risk factor chmp opinion
forward ec expect issu end januari februari final legal
bind decis applic eu member state ema recommend xeljanz use
caution patient high risk blood clot addit mainten dose mg twice daili
recommend patient uc high risk blood clot unless suitabl altern
treatment mg twice daili exceed ra patient advis risk vte
seek immedi medic treatment symptom develop treatment ema
recommend due increas risk infect patient older year age treat
xeljanz suitabl altern treatment recommend final chmp opinion
replac provision measur put place start review may contraind
mg twice daili dose xeljanz patient high risk blood clot lung chmp recommend
remov contraind chang come forc ec issu decis
novemb present posit result phase investig studi tofacitinib children
adolesc age two less polyarticular juvenil idiopath arthriti pajia late-
break oral present american colleg rheumatology/associ rheumatolog profession
annual meet trial met primari endpoint show patient pa-jia occurr diseas
flare patient treat tofacitinib significantli lower patient treat placebo week
common advers event studi treatment group upper respiratori tract infect headach
nasopharyng nausea pyrexia diseas progress vomit pa-jia case death major
advers cardiovascular event malign thrombosi opportunist infect tuberculosi intend
submit regulatori applic indic
xtandi enzalutamid -- decemb astella pharma inc announc fda approv
snda xtandi treatment patient metastat castration-sensit prostat cancer mcspc
estim men live mcspc form prostat cancer spread
part bodi still respond medic surgic treatment lower testosteron
pipelin develop comprehens updat develop pipelin publish today
avail www pfizer com/science/drug-product-pipelin includ overview research list
compound develop target indic phase develop well mechan action
candid phase candid phase registr
-- decemb poster present confer sangamo
therapeut inc present updat follow-up result phase alta studi evalu
investig gene therapi patient sever hemophilia data show
gener well toler demonstr sustain increas factor viii level follow treatment
week extent follow-up longest treat patient vg/kg dose cohort addit
manufactur technolog transfer transfer investig new drug applic
complet fourth-quart
decemb therav biopharma ireland limit subsidiari therav biopharma inc
therav biopharma announc compani enter global licens agreement
therav biopharma preclin program skin-target locally-act pan-janu kinas jak inhibitor
rapidli metabol compound program target valid pro-inflammatori pathway
specif design possess skin-select activ minim system exposur term
agreement therav biopharma receiv up-front cash payment million elig receiv
addit million develop sale mileston payment addit therav
biopharma elig receiv royalti world-wide net sale potenti product emerg
decemb announc ian read former chairman chief
execut offic jame kilt director sinc join board director viatri compani
form plan combin upjohn upon complet transact
anticip occur previous announc upon complet transact robert couri
serv execut chairman viatri board michael goettler current group presid upjohn
serv chief execut offic board member also previous announc ian read retir
board decemb jame kilt ceas member board immedi upon close
transact
decemb announc plan host investor day showcas compani mid-to-latestag
 pipelin progress commerci momentum across biopharma busi held tuesday march
global headquart new york ny busi execut scientif leadership provid
updat compani progress advanc pipelin specif product candid
blockbust potenti expect launch
addit detail see attach financi schedul product revenu tabl disclosur notic
follow acquisit divestitur impact financi result period present
juli glaxosmithklin plc gsk complet transact combin two
compani respect consum healthcar busi joint ventur jv oper gsk
consum healthcar name exchang contribut consum healthcar busi jv
receiv equiti stake jv gsk own remain jv upon close
transact deconsolid consum healthcar busi recogn pre-tax gain billion
billion net tax third-quart reflect differ fair valu equiti stake
jv carri valu consum healthcar busi accord domest
intern report financi result consum healthcar segment oper
result full-year reflect seven month consum healthcar segment domest oper eight
month consum healthcar segment intern oper record share earn
consum healthcar jv quarterli basi one-quart lag incom deductionsnet
commenc august therefor record share two month jv earn
gener third-quart pfizer oper result fourthquart
juli announc success complet acquisit array biopharma inc array
array portfolio includ approv combin use braftovi encorafenib mektovi binimetinib
treatment mutant unresect metastat melanoma
juli announc success complet acquisit privat held clinical-stag
revenu defin revenu accord gener accept account principl
report net income/ loss defin net income/ loss attribut pfizer inc accord gaap
report dilut earn per share ep report loss per share lp defin dilut ep lp
attribut pfizer inc common sharehold accord gaap
adjust incom compon adjust dilut ep defin report net
compon report dilut exclud purchas account adjust
acquisition-rel cost discontinu oper certain signific item may recur
gain complet joint ventur transact restructur charg legal charg net gain loss
invest equiti secur manag believ reflect on-going core oper
adjust cost sale adjust sell inform administr si expens adjust research
develop expens adjust incom /deduct incom statement line item prepar
basi therefor compon overal adjust incom measur describ
reviewnon-gaap measur adjust incom section pfizer report file
exhibit pfizer annual report fiscal year end decemb manag
use adjust incom among factor set perform goal measur perform overal
compani adjust incom import intern measur manag believ
investor understand perform enhanc disclos perform measur report
adjust incom certain compon adjust incom adjust dilut ep order portray result
compani major operationsth discoveri develop manufactur market sale prescript
medicin vaccinesprior consid certain incom statement element accompani
reconcili certain report non- adjust inform fourth quarter full year
adjust incom compon adjust dilut ep measur
view substitut net incom compon dilut ep
financi guidanc total compani reflect full-year contribut biopharma upjohn current
construct compani exclud impact pend upjohn combin
financi guidanc new pfizer reflect full-year pro forma view compani assum pend
upjohn combin complet begin therefor new pfizer reflect contribut
biopharma busi present manag exclud contribut pfizer meridian
subsidiari pfizer-mylan strateg collabor japan mylan-japan pfizer meridian subsidiari
mylan-japan manag pfizer biopharma busi financi guidanc new pfizer also includ
full-year effect follow item assum complet upjohn combin
billion net proce upjohn retain use repay exist
indebted
transaction-rel item incom transit servic agreement viatri
addit financi guidanc new adjust ibt adjust dilut reflect
pfizer share earn gener consum healthcar fourth-quart record
first-quart well share jv project earn first three quarter
financi guidanc upjohn assum full-year contribut upjohn busi present
manag includ contribut pfizer meridian subsidiari pfizermylan strateg collabor
japan mylan-japan pfizer meridian subsidiari mylan-japan manag pfizer biopharma
busi
fiscal year-end intern subsidiari novemb fiscal year-end
subsidiari decemb therefor fourth quarter full year subsidiari reflect three
twelv month end decemb decemb fourth quarter full year
subsidiari oper outsid reflect three twelv month end novemb
refer oper varianc press releas pertain period-over-period growth rate exclud
impact foreign exchang oper varianc determin multipli divid appropri
current period dollar result current period averag foreign exchang rate multipli
divid appropri amount prior-year period averag foreign exchang rate although exchang
rate chang part busi within control exchang rate chang howev
mask posit neg trend busi therefor believ present oper varianc provid
use inform evalu result busi
provid guidanc report financi measur revenu reconcili
forward-look non- financi measur directli compar report financi measur
forward-look basi unabl predict reason certainti ultim outcom pend
litig unusu gain loss acquisition-rel expens net gain loss invest equiti
secur potenti futur asset impair without unreason effort item uncertain depend
variou factor could materi impact report result guidanc period
financi guidanc total compani reflect follow
assum complet busi develop transact complet decemb
includ one-tim up-front payment associ transact
includ pfizer pro rata share consum healthcar anticip earn record
adjust one-quart lag therefor financi guidanc adjust
adjust dilut
reflect share jv earn gener fourth-quart record
firstquart well share jv project earn first three quarter
reflect anticip neg revenu impact billion due recent expect gener biosimilar
competit certain product recent lost anticip soon lose patent protect
exchang rate assum mid-januari reflect anticip unfavor impact
approxim billion revenu approxim adjust dilut result chang
foreign exchang rate rel dollar compar foreign exchang rate
guidanc adjust dilut assum dilut weighted-averag share outstand approxim
billion share assum share repurchas
upjohn process negoti term would transfer meridian
busi and/or certain asset current form part mylan-japan collabor viatri follow
complet propos combin upjohn assur agreement
transact result negoti parti unsuccess effort negoti term
potenti transact meridian busi and/or asset current form part
japan collabor remain
adjust incom tax margin adjust ibt margin defin revenu less sum adjust cost
sale adjust si expens adjust expens adjust amort intang asset adjust
percentag revenu adjust ibt margin present manag
believ perform measur supplement investor reader understand assess
financi perform new adjust ibt margin view substitut
 gaap incom tax margin
adjust earn interest tax depreci amort ebitda defin report
net compon adjust interest expens provision/ benefit tax income/ loss
depreci amort adjust exclud purchas account adjust acquisition-rel
cost discontinu oper certain signific item may recur gain
complet joint ventur transact restructur charg legal charg net gain loss invest
equiti secur manag believ reflect on-going core oper adjust
ebitda present manag believ perform measur supplement investor
reader understand assess financi perform upjohn adjust ebitda defin
measur financi perform consid altern net
cash flow oper determin accord
fourth quarter vs fourth quarter
sale percentag revenu rel flat
increas sale mainli driven unfavor chang product mix unfavor
impact foreign exchang well increas royalti expens base mix product sold
increas sell inform administr expens mostli driven addit
invest emerg market oncolog portfolio develop market market promot
expens associ launch vyndaqel may vyndamax septemb well
increas healthcar reform expens partial off-set favor impact foreign exchang
increas research develop expens mainli relat array acquisit well
increas medic spend new grow product
favor chang incom /deductionsnet primarili reflect million increas incom
collabor out-licens arrang sale compound/product right well favor impact
sale percentag revenu increas percentag point driven lower lyrica revenu
develop market primarili due multi-sourc gener competit began juli well
unfavor impact foreign exchang partial off-set lower royalti expens lyrica due patent
decreas sale mainli driven lower royalti expens due lyrica patent
expir multi-sourc gener competit began juli partial off-set unfavor impact
inform administr expens research develop expens
incom /deduct net rel unchang
sale percentag revenu rel flat
increas sale mainli driven unfavor chang product mix increas
royalti expens base mix product sold increas sale volum variou product within
product portfolio partial off-set favor impact foreign exchang
increas sell inform administr expens mostli driven addit
invest emerg market oncolog portfolio develop market market promot
expens associ launch vyndaqel may vyndamax septemb well
increas healthcar reform expens partial off-set favor impact foreign exchang
increas research develop expens mainli relat array acquisit well
increas medic spend new grow product
unfavor chang incom /deductionsnet primarili reflect million decreas incom
collabor out-licens arrang sale compound/product right million decreas
dividend incom invest viiv partial off-set increas royalty-rel incom mainli due
one-tim favor resolut second quarter legal disput million well
favor impact foreign exchang
sale percentag revenu increas percentag point driven lower lyrica revenu
develop market primarili due multi-sourc gener competit began juli partial
off-set lower royalti expens lyrica due patent expir
decreas sale mainli driven lower royalti expens due lyrica patent
expir multi-sourc gener competit began juli well favor impact foreign
sell inform administr expens decreas driven reduct field forc expens
well advertis promot expens develop market primarili relat lyrica well
favor impact foreign exchang partial off-set non-recurr one-tim gener
administr expens revers second third quarter invest china across key
research develop expens incom /deductionsnet rel unchang
acquisdata proud host leagu estim want opportun win free
subscript join acquisdata media telecommun leagu
pfizer inc research-bas global biopharmaceut compani appli scienc global resourc
bring therapi peopl extend significantli improv live discoveri develop
manufactur healthcar product global portfolio includ medicin vaccin well mani
acquisdata date busi intellig report cover develop world
report vast archiv corpor document list compani around world
abbott global diversifi healthcar compani central purpos help peopl live healthiest possibl
live offer broad portfolio market-lead product align favor long-term healthcar trend
develop develop market build strong foundat year success abbott
pois deliv top-tier growth expand margin strong cash flow increas return sharehold
compani take toughest health challeng treat diseasesw aim make
remark impact peopl live highli focus research-driven biopharmaceut
today employe around world focu deliv transform medicin therapi
allergan plc nyse agn headquart dublin ireland global pharmaceut leader focus
develop manufactur commerci brand pharmaceut devic biolog surgic regen
medicin product patient around world
one world largest pharmaceut servic compani serv unit state
canada select global market focu pharmaceut suppli channel servic
pharmaceut manufactur healthcar provid compani servic solut rang nich premium
logist pharmaceut packag reimburs pharmaceut consult servic scale
posit healthcar industri valu bring channel help busi continu
commit unlock potenti biolog patient suffer seriou ill discov
develop manufactur deliv innov human therapeut approach begin use tool like
advanc human genet unravel complex diseas understand fundament human biolog
global science-l biopharmaceut busi innov medicin use million
time world around us chang burden diseas increas respond
increas focu growth innov patient-centr technolog digit
data advanc cutting-edg scienc
bausch health compani inc formerli valeant pharmaceut multi-national specialti pharmaceut
compani base laval canada bausch health focus improv peopl live health care
product deliv commit patient health care provid stakehold societi
build innov compani dedic advanc global health
baxter touch live million peopl around world everi day product therapi found
throughout hospit clinic er pharmaci icu well advanc patient
care home inc fortun american health care compani headquart
bristol-my squibb differenti compani led uniqu biopharma strategi leverag reach
resourc major pharma compani pair entrepreneuri spirit agil biotech firm work
everi day deliv innov medicin patient seriou life-threaten diseas
lilli found colonel eli lilli man commit creat high-qual medicin met real need
era unreli elixir peddl question charact charg gener employe
follow take find make better better
consid founder industri genentech member roch group deliv
promis biotechnolog year
genentech biotechnolog compani dedic pursu groundbreak scienc discov develop
medicin peopl seriou life-threaten diseas transform discoveri includ first
target antibodi cancer first medicin primari progress multipl sclerosi
science-l global healthcar compani special purpos help peopl feel better live
glaxosmithklin plc form result merger glaxo wellcom plc smithklin
beecham plc although histori trace back year london plough court pharmaci
johnson johnson believ good health foundat vibrant live thrive commun forward
progress that year aim keep peopl well everi age everi stage
life today world largest broadli base healthcar compani commit use reach
size good strive improv access afford creat healthier commun put healthi
mind bodi environ within reach everyon everywher
johnson johnson incorpor state new jersey
era unpreced complex healthcar patient care mani
organ deliv care need get much healthier
vision improv care everi set one product one partner one patient time
make happen everi day touch virtual everi aspect healthcar
global healthcar compani histori work make differ
make differ live peopl global innov medicin vaccin anim health
product commit premier research-intens biopharmaceut compani dedic
provid lead innov solut today futur
discov develop provid innov product servic save improv live around world
novarti creat merger ciba-geigi sandoz novarti predecessor compani
trace root back year rich histori develop innov product
purpos reimagin medicin improv extend peopl live use innov scienc
technolog address societi challeng healthcar issu discov develop breakthrough
treatment find new way deliv mani peopl possibl also aim reward
invest money time idea compani
novo nordisk drive chang defeat diabet seriou chronic condit
novo nordisk global healthcar compani year innov leadership diabet care
heritag given us experi capabl also enabl us help peopl defeat seriou chronic
condit rare bleed disord growth hormon relat disord obes
headquart denmark novo nordisk employ approxim peopl countri market
product countri
start humbl begin year ago rural michigan today one largest
luther perrigo owner gener store apple-dri busi idea packag
distribut patent medicin household item countri store luther launch privat label concept
way enhanc custom loyalti addit cost offer imprint store name label
epsom salt sweet oil bay rum dozen wet dri good stock gener store
regeneron pharmaceut inc lead scienc technolog compani deliv life-
transform medicin seriou diseas inc compani headquart eastview
near tarrytown new york found physician-scientist year ago science-driven approach result
six fda-approv medicin numer product candid rang diseas includ asthma pain
cancer infecti diseas
field human health undergo profound scientif technolog chang point way major
therapeut innov patient
sanofi innov dna mission har new technolog new way work find
healthcar solut around world research develop strategi innov view
three angl scienc technolog digit
build strong global footprint size scale teva reaffirm commit place peopl
center strategi enabl mani possibl live better healthier day develop
produc market afford high qualiti gener drug well innov specialti pharmaceut
activ pharmaceut ingredi
biopharmaceut compani across america peopl go work everi day mission advanc
innov treatment cure make differ million patient live
commit ensur patient access medicin preserv strong economi support vibrant
research valuabl job also stand behind medicin creat valu provid
patient across health care system
new era medicin breakthrough scienc transform care approach treat
patient robust invest research develop biopharmaceut compani result
advanc discoveri unlik anyth weve seen applic genom develop person
medicin enabl physician tailor treatment uniqu need patient immunotherapi
har patient immun system fight variou condit includ cancer rare diseas
last decad alon biopharmaceut compani invest half trillion dollar invest
begin yield result open door entir new way tackl complex difficult
treat diseas time
progress see today revolution treat diseas save patient live improv qualiti life
public health across broad rang chronic rare condit new era medicin mani diseas
previous regard deadli manag potenti curabl today medicin
clinic develop around world across medicin pipelin clinic develop
potenti first-in-class treatment repres entir new approach treat diseas futur
never brighter research explor new frontier year ago may regard
scienc fiction transform patient live
new era medicin isnt good news healthit good news health care system societi
new innov medicin keep patient healthi hospit reduc need costli emerg
room visit hospit stay surgeri long-term care save money patient nation health
system look forward medicin best bet confront countri biggest health cost driver chronic
diseas condit cancer diabet heart diseas lead caus death disabl
unit state patient condit account health care spend iv continu
advanc treatment indispens address societi health econom challeng year
invest biopharmaceut innov improv save live also drive tremend contribut
american economi america role leader medic innov biopharmaceut
compani invest billion unit state industri america
industri support million job across countri employe across compani
go work everi day research develop new treatment cure patient occur even face
continu setback develop timelin extens cost high rate scientif
new medicin transform care patient fight debilit diseas like cancer hepat heart diseas
mani rare condit yet midst progress spend retail physician-administ medicin
continu repres overal health care spend next decad mani new medicin
revolution care patient yet spend medicin project continu remain small stabl
share health care spend occur market-bas system unit state promot
incent continu innov increas patient access need medicin leverag competit
control cost
 market highli competit robust competit brand gener andincreasinglybiosimilar
altern result medicin price fall dramat competit occur among brand name medicin
price fall even gener introduc market fact prescript fill patient
unit state gener typic cost fraction price initi brand medicin ix expect
dynam continu year ahead sinc billion brand sale project face gener
biosimilar competit
anoth reason current marketplac medicin success control cost health insur
pharmaci benefit manag pbm power sophist purchas use leverag negoti
discount rebat list price medicin today top three pbm manag
prescript fill unit state xi averag list price medicin given
rebat discount insur compani govern pbm entiti suppli chain often
requir larg rebat medicin cover xii fact evid suggest negoti discount rebat
price concess doubl sinc total billion
continu growth rebat discount keep prescript medicin price growth slowest rate
year doesnt feel way mani patient often negoti save make way
patient increasingli ask pay pocket innov medicin unlik care receiv
in-network hospit physician offic patient high deduct coinsur pay cost share base
list price medicin even though insur may receiv steep discount half commerci
insur patient out-of-pocket spend brand medicin base full list price xiv mean patient
high deduct health plan pay list price month medicin may pay hundredsor even
thousandsmor year insur pay medicin
insur increasingli expos patient list price medicin patient seen out-of-pocket cost
continu grow pharmaci commerci insur patient deduct seen out-of-pocket
cost brand medicin increas sinc
though rebat discount grown substanti health plan typic use portion negoti
rebat reduc premium enrolle rather directli lower cost patient face high cost-shar
due deduct coinsur creat system payer requir patient pay pocket
rebat save spread among health plan enrolle form lower premium ask sicker
patient subsid premium healthier enrolle exact opposit health insur suppos
chang need ensur billion negoti rebat discount price concess
use lower cost patient pharmaci counter research show high cost share associ
lower medic adher increas abandon rate put patient abil stay need
therapi risk share negoti discount could save certain commerci insur patient high deduct
coinsur annual increas premium less xx medicar
part polici ensur save negoti discount pass medicar beneficiari would also
improv afford senior strengthen competit incent part program exampl typic
medicar beneficiari diabet take five medicin could save year out-of-pocket cost
america biopharmaceut compani commit work policymak stakehold advanc
market-bas solut aim toward ensur patient access need treatment support continu
innov drive valu health care system address misalign suppli chain incent
statu quo work patient misalign incent health care system need chang
rebat price concess payer receiv biopharmaceut compani use lower
cost share patient pharmaci counter need improv afford predict
cost senior medicar part current limit out-of-pocket expens adopt out-
of-pocket cap medicar part would align benefit commerci insur market ensur
beneficiari face catastroph ill abl afford treatment provid patient
transpar medicin cost phrma member voluntarili direct patient link cost inform
direct-to-consum dtc televis advertis phrma also launch medicin assist tool
provid link referenc dtc televis advertis help patient connect financi assist
make medicin afford move toward health care system focus result measur
valu eye patient enabl privat sector develop new better way pay
medicin move toward value-driven health care system includ develop data provid
patient physician easy-to-us inform differ medicin work creation better measur
qualiti care take account patient feel reform allow new way insur pay
medicin advanc research method relat valu assess encompass outcom
matter patient famili import step toward goal
commit advanc market-bas reform promot competit modern drug discoveri
develop process get medicin approv effici ensur safeti need modern
drug discoveri develop process equip regul new technolog expertis keep
centuri scienc also need ensur time review approv gener biosimilar medicin
patient benefit less expens gener biosimilar medicin replac treatment follow expir
patent data protect addit unit state must continu incentiv medic innov
competit strong intellectu properti incent enforc within outsid unit
market-bas health care system work well control cost done help work even
better patient current system creat misalign incent pbm other suppli chain
favor medicin high list price rebat impact patient afford reform need
prevent pbm other suppli chain paid list price medicin instead fee base
valu servic provid wrong way address misalign incent greater govern
intervent marketplac negoti adopt harm practic countri restrict patient
access need medicin strengthen health care system must also address misalign profit incent
fuel hospit markup medicin provid consolid address misalign incent
present opportun reduc largest fastest contributor health care costshospit spend
pharmaceut research manufactur america phrma
acquisdata date busi intellig report cover develop world
report vast archiv corpor document list compani around world
